Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Guo-Long Bu
Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research
Guo-Long Bu, Li-Na Chen, and Pei-Huang Wu contributed equally to this work. G.-L.Bu, L.-N.Chen, P.-H.Wu, M.-S.Zeng, and Q.Zhong, “Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research,” Journal of Medical Virology98 (2026): e70961, https://doi.org/10.1002/jmv.70961. Conflicts of Interest The authors declare no conflicts of interest.
A large-scale population-based study reveals that gp42-IgG antibody is protective against EBV-associated nasopharyngeal carcinoma
Abstract Introduction The incidence of nasopharyngeal carcinoma (NPC) demonstrates a striking geographical variation (1). In endemic regions such as southern China, the age-adjusted incidence can reach 23 of 100,000 in men and 7 of 100,000 in women, which is 10-fold higher than the global incidence (2). The regional variation implies a complex interplay of genetic predisposition, environmental risk factors, and, notably, EBV infection (1, 3).
Potent human monoclonal antibodies targeting Epstein-Barr virus gp42 reveal vulnerable sites for virus infection
Highlights • Human anti-gp42 mAbs can neutralize EBV infection in both B and epithelial cells • 2B7 and 2C1 target different gp42 epitopes, distinct from the HLA-II binding site • High prevalence of 2C1-like antibodies among individuals infected with EBV • 2C1 has shown significant protection against EBV infection in humanized mice models Summary Epstein-Barr virus (EBV) is linked to various malignancies and autoimmune diseases, posing a significant global health challenge due to the lack of...
mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice
1 Introduction Epstein-Barr virus (EBV) is the first identified oncogenic virus in humans and has infected more than 90% of the global population[1] It mainly infects epithelial cells and B cells and accounts for ≈2% of human malignant tumors.[2, 3] Since the first report of EBV in Burkitt lymphoma in 1964, EBV has been closely linked to numerous lymphoid and epithelial malignancies, such as Hodgkin lymphoma, Burkitt lymphoma, gastric cancer, nasopharyngeal carcinoma (NPC), and...
Anti‐EBV antibodies: Roles in diagnosis, pathogenesis, and antiviral therapy
Abstract Epstein-Barr virus (EBV) infection is prevalent in global population and associated with multiple malignancies and autoimmune diseases. During the infection, EBV-harbored or infected cell-expressing antigen could elicit a variety of antibodies with significant role in viral host response and pathogenesis. These antibodies have been extensively evaluated and found to be valuable in predicting disease diagnosis and prognosis, exploring disease mechanisms, and developing antiviral agents.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Guo-Long
Contact Guo-Long, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack